Revolution Medicines Inc (RVMD) Stock: What Does the Chart Say Tuesday?

Overall market sentiment has been neutral on Revolution Medicines Inc (RVMD) stock lately. RVMD receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Revolution Medicines Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock is trading at $17.51 as of 3:55 PM on Tuesday, Jun 28, a decline of -$0.99, or -5.35% from the previous closing price of $18.50. The stock has traded between $17.39 and $18.67 so far today. Volume today is low. So far 296,410 shares have traded compared to average volume of 851,405 shares. To screen for more stocks like Revolution Medicines Inc click here.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.